

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: October 21, 2025
PDL Changes Effective Date: January 1, 2026



The following changes will be made to the Preferred Drug List (PDL), effective January 1, 2026, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Sickle Cell Agents	Casgevy (exagamglogene autotemcel)
Sickle Cell Agents	Lyfgenia (lovotibeglogene autotemcel)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Antivirals, Topical	Zelsuvmi (berdazimer)
Bone Resorption Suppression and Related Agents	Bomyntra (denosumab-bnht)
Cytokine & CAM Antagonist	Anzupgo (delgocitinib)
Hereditary Angioedema Treatments	Dawnzera (donidalorsen)
Hereditary Angioedema Treatments	Ekterly (sebetralstat)
Hypoglycemics, Insulins & Related Agents	Kirsty (insulin aspart-xjhz)
Hypoglycemics, Insulins & Related Agents	Merilog (insulin aspart-szjj)
Miscellaneous Brand/Generic, Miscellaneous	Brinsupri (brensocatib)
Miscellaneous Brand/Generic, Miscellaneous	Harliku (nitisinone)
Muscular Dystrophy Agents	Jaythari (deflazacort)